|
|
 |
|
|
|
|
Safety and EfficacyChemistry, Pharmacy and Manufacturing. A. C. Cartwright and B. R. Matthews, Eds. Publ. by Ellis Horwood, Chichester, West Sussex, 1994. |
|
|
|
|
|
|
|
|
4. ICH2. International Conference on Harmonisation Safety Topic S3A: Note for guidance on Toxicokinetics. The assessment of systematic exposure in toxicity studies. Draft 10 Step 4 document. EFPIA, Brussels, 1994. |
|
|
|
|
|
|
|
|
5. D. A. Waterman. A guide to expert systems Reading MA. Addison-Wesley, New York, 1986. |
|
|
|
|
|
|
|
|
6. C. Hansch. Quantitative structure-activity relationships in drug design. In Drug Design. Vol. 1. 1971. E. J. Ariens, Ed. Academic Press, New York, p. 271342. |
|
|
|
|
|
|
|
|
7. M. Gumbleton and W. Sneader. Pharmacokinetic considerations in rational drug design. Clin. Pharmacokin. 26: 161168, 1994. |
|
|
|
|
|
|
|
|
8. B. Testa and P. Jenner. A structural approach to selectivity in drug metabolism and disposition. In Concepts in Drug Metabolism, Part A. P. Jenner and B. Testa, Eds. Marcel Dekker, New York, 1980, p. 53176. |
|
|
|
|
|
|
|
|
9. R. A. Herman and P. Veng-Pedersen. Quantitative structure-pharmacokinetic relationships for systemic drug distribution kinetics not confined to a congeneric series. J. Pharm. Sci. 83: 423428, 1994. |
|
|
|
|
|
|
|
|
10. K. H. Kim. Quantitative structure-activity relationships of the metabolism of drugs by uridine diphosphate glucuronosyltransferase. J. Pharm. Sci. 80: 966970, 1991. |
|
|
|
|
|
|
|
|
11. C. Hansch, J. P. Bjorkroth, and A. Leo. hydrophobicity and central nervous system agents: on the principle of minimal hydrophobicity in drug design. J. Pharm. Sci. 76: 663687, 1987. |
|
|
|
|
|
|
|
|
12. E. Holmes, B. C. Sweatman, M. E. Bollard, C. A. Blackledge, C. R. Beddell, I. D. Wilson, J. C. Lindon, and J. K. Nicholson. Prediction of urinary sulphate and glucuronide conjugate excretion for the substituted phenols in the rat using quantitative structure-metabolism relationships. Xenobiotica 25: 12691282, 1995. |
|
|
|
|
|
|
|
|
13. R. Lahana. Tools for structure activity relationships: a comprehensive software. Human Exp. Toxicol. 14: 522, 1995. |
|
|
|
|
|
|
|
|
14. B. Ajay. A unified framework for using neural networks to build QSARs. J. Med. Chem. 36: 35653571, 1993. |
|
|
|
|
|
|
|
|
15. S. Hirano, I. Nakagome, H. Hirano, F. Yoshi, and I. Moriguchi. Noncongeneric structure pharmacokinetic property correlation studies using fuzzy adaptive least squares: volume of distribution. Bilo. Pharm. Bull. 17: 686690, 1994. |
|
|
|
|
|
|
|
|
16. D. F. V. Lewis, H. Moereels, B. G. Lake, C. Ioannides, and D. V. Parke. Molecular modeling of enzymes and receptors involved in carcinogenesis QSARs and COMPACT-3D. Drug Metabolism Revs. 26: 261285, 1994. |
|
|
|
|
|
|
|
|
17. D. F. V. Lewis, B. G. Lake, and D. V. Parke. Molecular orbital-generated QSARs in a homologous series of alkoxyresorufins and studies of their interactive docking with P450s. Xenobiotica 25: 13551370, 1995. |
|
|
|
|
|
|
|
|
18. XENO. A modular FORTRAN program runing on a Digital PDP-10 computer at the SUMEX-AIM (Stanford University Medical Experiment-Artificial Intelligence in Medicine) facility, 1980. |
|
|
|
|
|
|
|
|
19. CompuDrug. Metabol Expert. Expert Advisory systems for the prediction of the metabolism of exogenous compounds in many different living organisms. CompuDrug Chemistry Ltd., Budapest, Hungary, 1990. |
|
|
|
|
|